Eupraxia Pharmaceuticals Inc.

About

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Victoria, British Columbia. The company specializes in developing targeted, extended-release therapies using its proprietary Diffusphere™ technology. This innovative platform allows for precise drug delivery to diseased tissues, enhancing efficacy, safety, and convenience for patients with inflammatory diseases, oncology, pain, and other conditions. Eupraxia's clinical pipeline includes EP-104GI, a lead candidate for eosinophilic esophagitis (EoE), which has shown promising results in clinical trials. The company focuses on high-need areas such as gastrointestinal and musculoskeletal diseases, aiming to provide long-term relief from a single treatment. Eupraxia is publicly traded on NASDAQ and TSX under the ticker EPRX and is committed to advancing its research and development efforts in the life sciences sector.